東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Role of mTORC1 in BDK-Mediated Improvements in Cardiometabolic Parameters.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Role of mTORC1 in BDK-Mediated Improvements in Cardiometabolic Parameters./
作者:	Bollinger, Eliza.
面頁冊數:	1 online resource (67 pages)
附註:	Source: Masters Abstracts International, Volume: 83-11.
Contained By:	Masters Abstracts International83-11.
標題:	Biology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29163509click for full text (PQDT)
ISBN:	9798426821033

Role of mTORC1 in BDK-Mediated Improvements in Cardiometabolic Parameters.
Bollinger, Eliza.

Role of mTORC1 in BDK-Mediated Improvements in Cardiometabolic Parameters. - 1 online resource (67 pages)

Source: Masters Abstracts International, Volume: 83-11.

Thesis (A.L.M.)--Harvard University, 2022.

Includes bibliographical references

Multiple recent studies from various labs have shown improvements in several endpoints in pre-clinical models after treatment with the branched chain ketoacid dehydrogenase kinase (BDK) inhibitor BT2, yet there is still a lack of mechanistic understanding underlying these improvements. Because BT2 leads to decreased plasma and skeletal muscle levels of branched chain amino acids (BCAAs) and branched chain ketoacids (BCKAs) (Neinast et al. 2019), which activate the mammalian target of rapamycin complex 1 (mTORC1), there may also be a decrease in mTORC1 signaling with BT2 in in vivo models of cardiometabolic disease. Increased mTORC1 activity has been implicated in many metabolic disorders (Cheon and Cho 2021; Liu and Sabatini 2020). The goal of this research was to understand whether positive effects seen in multiple animal models of cardiovascular and metabolic disorders with BDK inhibition such as reduced hyperglycemia and hyperinsulinemia may be due to decreased mTORC1 activity. Here, it is demonstrated that in a mouse model of cardiometabolic disease, mTORC1 signaling is decreased as measured by phosphorylation of the mTORC1 downstream target, S6 ribosomal protein, in heart tissue after chronic treatment of BT2. However, compared to healthy mice on standard chow diet, mice with cardiometabolic disease on 60% high fat diet (HFD) had a decrease in mTORC1 activity, which may be explained by the differences in diet (Kimball et al. 2015). Mice treated with BT2 displayed improvements in glycemia and hyperinsulinemia, but acute co-treatment of mice with BT2 and mTORC1 activator NV-5138 resulted in a trending increase in glucose and insulin compared to mice treated with BT2 alone. These results suggest that BT2 and BDK inhibition-mediated positive effects observed in metabolic disease may be in part due to decreased mTORC1 activity.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2023

Mode of access: World Wide Web

ISBN: 9798426821033Subjects--Topical Terms:

522710
Biology.
Subjects--Index Terms:

Branched chain ketoacid dehydrogenase kinase inhibitorIndex Terms--Genre/Form:

542853
Electronic books.

Role of mTORC1 in BDK-Mediated Improvements in Cardiometabolic Parameters.
LDR:03266nmm a2200397K 4500 001 2359744
005 20230917195233.5
006 m o d
007 cr mn ---uuuuu
008 241011s2022 xx obm 000 0 eng d
020 $a 9798426821033
035 $a (MiAaPQ)AAI29163509
035 $a AAI29163509
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Bollinger, Eliza. $3 3700363
245 1 0 $a Role of mTORC1 in BDK-Mediated Improvements in Cardiometabolic Parameters.
264 0 $c 2022
300 $a 1 online resource (67 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Masters Abstracts International, Volume: 83-11.
500 $a Advisor: Roth Flach, Rachel; Denkin, Steven.
502 $a Thesis (A.L.M.)--Harvard University, 2022.
504 $a Includes bibliographical references
520 $a Multiple recent studies from various labs have shown improvements in several endpoints in pre-clinical models after treatment with the branched chain ketoacid dehydrogenase kinase (BDK) inhibitor BT2, yet there is still a lack of mechanistic understanding underlying these improvements. Because BT2 leads to decreased plasma and skeletal muscle levels of branched chain amino acids (BCAAs) and branched chain ketoacids (BCKAs) (Neinast et al. 2019), which activate the mammalian target of rapamycin complex 1 (mTORC1), there may also be a decrease in mTORC1 signaling with BT2 in in vivo models of cardiometabolic disease. Increased mTORC1 activity has been implicated in many metabolic disorders (Cheon and Cho 2021; Liu and Sabatini 2020). The goal of this research was to understand whether positive effects seen in multiple animal models of cardiovascular and metabolic disorders with BDK inhibition such as reduced hyperglycemia and hyperinsulinemia may be due to decreased mTORC1 activity. Here, it is demonstrated that in a mouse model of cardiometabolic disease, mTORC1 signaling is decreased as measured by phosphorylation of the mTORC1 downstream target, S6 ribosomal protein, in heart tissue after chronic treatment of BT2. However, compared to healthy mice on standard chow diet, mice with cardiometabolic disease on 60% high fat diet (HFD) had a decrease in mTORC1 activity, which may be explained by the differences in diet (Kimball et al. 2015). Mice treated with BT2 displayed improvements in glycemia and hyperinsulinemia, but acute co-treatment of mice with BT2 and mTORC1 activator NV-5138 resulted in a trending increase in glucose and insulin compared to mice treated with BT2 alone. These results suggest that BT2 and BDK inhibition-mediated positive effects observed in metabolic disease may be in part due to decreased mTORC1 activity.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2023
538 $a Mode of access: World Wide Web
650 4 $a Biology. $3 522710
650 4 $a Health sciences. $3 3168359
650 4 $a Biochemistry. $3 518028
653 $a Branched chain ketoacid dehydrogenase kinase inhibitor
653 $a BT2
653 $a Cardiovascular and metabolic disorders
653 $a BDK inhibition
653 $a mTORC1 activity
655 7 $a Electronic books. $2 lcsh $3 542853
690 $a 0306
690 $a 0566
690 $a 0487
710 2 $a ProQuest Information and Learning Co. $3 783688
710 2 $a Harvard University. $b Extension Studies. $3 3560717
773 0 $t Masters Abstracts International $g 83-11.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29163509 $z click for full text (PQDT)